Sotera Health Company
Valuation each multiple against its own 5-year range
Vs. peers Diagnostics & Research
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Sotera Health Company (SHC) | 4.54B | 26.52 | 6.20 | 0.00% |
| Thermo Fisher Scientific (TMO) | 248.08B | 35.31 | 4.53 | 0.27% |
| Danaher (DHR) | 155.03B | 36.12 | 2.89 | 0.69% |
| IDEXX Laboratories Inc (IDXX) | 53.28B | 45.57 | 28.50 | 0.00% |
| Agilent Technologies (A) | 48.04B | 33.61 | 6.52 | 0.59% |
| Waters (WAT) | 43.29B | 184.29 | 2.83 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 0.9% above Morningstar's fair value estimate.
Fair value
Sotera Health Co is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 5% premium over our quantitative fair value estimate of $15.76 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating.
The firm's liquidity weakens our quantitative valuation. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. For example, the firm's median trading volume over the past 60 days lies in the top 30% compared with global peers. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. We believe this is a sign that shares could be overvalued.
The company's unfavorable dividend structure is an additional cause for concern. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, falls in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-11-20 16:00:57 · For reference only, not investment advice and not tailored to your situation.
Sotera Health Company discussion 0 comments